Rafael Holdings, Inc. (RFL) Research

Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Market snapshot

Symbol
RFL
Price
$2.73
Day change
+3.80%
Market cap
$100.3M
P/E ratio
-4.30x
52-week range
1.12-2.8
Sector
Real Estate
Industry
Real Estate - Services

Peer companies

  • Ashford Hospitality Trust, Inc. (AHT)
  • reAlpha Tech Corp. Common Stock (AIRE)
  • Fathom Holdings Inc. (FTHM)
  • Ohmyhome Limited (OMH)
  • Offerpad Solutions Inc. (OPAD)
  • Sachem Capital Corp. (SACH)
  • Sotherly Hotels Inc. (SOHO)
  • Token Communities Ltd. (TKCM)

Recent insider activity

  • JONAS HOWARD S — A-Award (142857 shares) on 2026-06-13
  • JONAS HOWARD S — F-InKind (8786 shares) on 2026-06-13
  • Polinsky David — F-InKind (2318 shares) on 2026-03-21
  • JONAS HOWARD S — F-InKind (9826 shares) on 2026-03-13
  • Sieger Markus — A-Award (29528 shares) on 2026-01-28

Open Rafael Holdings, Inc. (RFL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.